Ironwood Pharmaceuticals IRWD Increase Decrease In Accrued Research And Development Expense
Increase Decrease In Accrued Research And Development Expense at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept irwd:IncreaseDecreaseInAccruedResearchAndDevelopmentExpense.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's increase decrease in accrued research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's increase decrease in accrued research and development expense?
- Ironwood Pharmaceuticals (IRWD) reported increase decrease in accrued research and development expense of -$1.1M in Q1 2026.
- How has Ironwood Pharmaceuticals's increase decrease in accrued research and development expense changed year-over-year?
- Ironwood Pharmaceuticals's increase decrease in accrued research and development expense decreased by 4.6% year-over-year, from -$1.05M to -$1.1M.
- What does increase decrease in accrued research and development expense mean?
- This metric tracks the net change in liabilities related to research and development activities that have been incurred but not yet paid in cash. It reflects the timing difference between the recognition of R&D expenses in the income statement and the actual cash outflow to vendors or partners. A significant change can indicate shifts in the pace of clinical trials or the timing of milestone payments to collaborative partners.